Skip to content

Leo Study Unstable Asthma

Engineering Validation of Leo Device to Assess Clinical Control of Children Recovering From Acute Asthma Exacerbation

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05308277
Enrollment
30
Registered
2022-04-04
Start date
2022-04-27
Completion date
2023-04-30
Last updated
2022-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma in Children

Brief summary

This is a prospective, observational study to investigate the agreement of the Leo device signal derivation with gold standard asthmatic testing in recently exacerbated asthmatic children. This study is designed for engineering validation of a wireless, wearable device (Leo) for assessing clinical control of children recovering from acute respiratory event such as asthma attack. The Leo device will monitor chest impedance, ECG and body position to calculate parameters such as respiration rate, heart rate, lung volume, tidal breathing flow and volume curves, and body position. These parameters will then be used to train and algorithm to assess clinical control of asthma.

Interventions

DEVICELeo device monitoring

After consent and enrollment, the child's respiratory impedance will be continuously recorded using the Leo device throughout the day and night during the entire hospital stay or ED visit. The device may be taken off for up to 1 hour per day (i.e., break during bath / shower time). The device will be applied to the skin overlying the mid-sternum area on the chest wall after cleaning of the skin with an alcohol swab after consent has been obtained. The device will be changed every 72 hours or earlier, by the participant's guardian, depending on signs of defect in the signal quality or battery exhaustion, based on daily check of the signal by the research team. Remote monitoring of the child's chest impedance will continue using the Leo device after discharge from hospital/ED for 7 days.

Sponsors

ResMed
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Intervention model description

Engineering validation of a lung function monitoring device

Eligibility

Sex/Gender
ALL
Age
2 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

* Children aged ≥2 years old and \<18 years old at time of consent * Children with a legal guardian able to sign consent for study participation * Children and caregivers able to read and understand English or Spanish * Children who are currently hospitalized with acute exacerbation of asthma * Child's caregiver is able to communicate using SMS * Child has an asthma inhaler

Exclusion criteria

* Children with complex medical conditions which may hinder their ability to complete protocol assessments * Children with an active skin condition involving the area on the chest wall where the Leo device will be attached. E.g. inflamed and/or infected eczema or other skin conditions involving the anterior chest wall at the time of recruitment * Children with any implanted medical devices, E.g. cardiac pacemaker * Children with any history of known allergic reaction to adhesives or hydrogels, as the ones used with the Leo device

Design outcomes

Primary

MeasureTime frameDescription
Airway resistance through oscillometry testBaseline visit and 7 days post hospital/ED dischargeAsthma severity measures will be determined through oscillometry test at baseline and follow-up visit. Leo measurements will be assessed for agreement with oscillometry measures.
Asthma Flare-up diaryFollow-up for 7 days post hospital/ED dischargeSelf-reported asthma flare-up diary score will be measured daily during the remote (at home) period in between visits.
CASI questionnaireBaseline visit and 7 days post hospital/ED dischargeQuestionnaire will be used to determine asthma severity during baseline and follow-up visit. CASI scores include five domains: day symptoms and albuterol use, night symptoms and albuterol use, controller treatment, lung function measures, and exacerbations. Range is from 0 -17, with a higher score indicating worse asthma severity

Secondary

MeasureTime frameDescription
Inhaler usageFollow-up for 7 days post hospital/ED dischargePropeller sensor will include measures of time stamped data of inhaler usage (controller and rescue inhalers)
Tidal breathing from PNT device7 days post hospital/ED dischargeAgreement and correlation in tidal breathing parameters between Leo and the pneumotachograph (PNT) device. The PNT device parameters are considered standard of care, and will be compared against Leo device to evaluate agreement.

Other

MeasureTime frame
Frequency and severity of localized skin reaction including redness and irritation / itchiness / discomfort.7 days post hospital/ED discharge

Countries

United States

Contacts

Primary ContactFaizan Javed, PhD
faizan.javed@resmed.com.au+61 413624856

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026